Eloxatin Symptom-Based Clinical Benefit Could Support Full Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Demonstration of symptom-based clinical benefit could be used to support full approval of Sanofi-Synthelabo’s second-line colorectal cancer therapy Eloxatin, FDA indicated in review documents for the Aug. 9, 2002, accelerated approval.